The biotechnology company Cytokinetics has completed patient enrollment in its Phase III randomized, double-blind, placebo-controlled clinical trial of tiramsemtiv in ALS, named VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS). Over 700 patients from 81 research centers in 11 countries have enrolled in the trial, aimed at testing the effect of the skeletal muscle activator tirasemtiv on slow viral capacity (SVC), a measure of respiratory function (see July 2015 news, March 2016 news). Additional measures of muscles strength and motor function will also be assessed as secondary outcome measures. The company anticipates announcing results of the clinical trial in the second half of 2017.
Click here to read the press release.